WESTMINSTER, Colo., Sept. 22 /PRNewswire-FirstCall/ -- Allos Therapeutics,
Inc. (Nasdaq: ALTH) today announced that the Company will participate in the
UBS 2005 Global Life Sciences Conference, to be held September 26th - 29th in
New York City. Michael E. Hart, the Company's President and Chief Executive
Officer, will give a 30-minute corporate overview on Thursday, September 29th
at 9:30 AM ET.
The presentation will be webcast live and may be accessed by visiting the
Allos website at http://www.allos.com. A replay of the webcast will also be
available on the Company's website until Saturday, October 29, 2005.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company
focused on developing and commercializing innovative small molecule
therapeutics for the treatment of cancer. Our lead product candidate,
EFAPROXYN(TM) (efaproxiral), is a synthetic small molecule designed to
sensitize hypoxic, or oxygen-deprived, tumor tissue during radiation therapy.
EFAPROXYN is currently being evaluated as an adjunct to whole brain radiation
therapy in a pivotal Phase 3 trial in women with brain metastases originating
from breast cancer. Our other product candidates are: PDX (pralatrexate), a
small molecule chemotherapeutic agent (DHFR inhibitor) currently under
investigation as both a single agent and in combination therapy regimens in
patients with non-small cell lung cancer and Non-Hodgkin's lymphoma; and RH1,
a small molecule chemotherapeutic agent bioactivated by the enzyme
DT-diaphorase currently under evaluation in patients with advanced solid
tumors. For more information, please visit the Company's web site at:
http://www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements that
involve significant risks and uncertainties, including those to be discussed
in the presentation and others that can be found in the "Risk Factors" section
of the Company's Form 10-K for the year ended December 31, 2004 and in the
Company's periodic reports on Form 10-Q and Form 8-K. The Company does not
undertake any obligation to update any forward-looking statements contained in
the anticipated presentation as a result of new information, future events or
otherwise. The Company cautions investors not to place undue reliance on the
forward-looking statements contained in the presentation. No forward-looking
statement can be guaranteed and actual events and results may differ
materially from those projected.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com
CONTACT:
Jennifer Neiman, Manager, Corporate
Communications, of Allos Therapeutics, +1-720-540-5227,
jneiman@allos.com
|
